We are proud to announce the release of Horizon Scanning 2020 where Omakase Consulting is working with Orphar-SEFH
https://twitter.com/sefh_/status/1363847789315301378?s=20 [...]
52% of innovations approved in 2020 have some limitation in their prescription or dispensing
https://www.diariofarma.com/2021/02/09/el-52-de-las-innovaciones-aprobadas-en-20 [...]
CHMP positive opinions January 2021
https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-product [...]
-
Delighted to share an interesting debate, coordinated with Zogenix, about the Multiple Criteria Decision Analysis (MCDA) methodology as a new tool to empowerment of patients suffering from Dravet Syndrome.Delighted to share an interesting debate, coordinated with Zogenix, about the Multiple Criteria Decision Analysis (MCDA) methodology as a new tool to empowerment of patients suffering from Dravet Syndrome.
Delighted to share an interesting debate, coordinated with Zogenix, about the Multiple Criteria Decision Analysis (MCDA) methodology as a new tool to empowerment of patients suffering from Dravet Syndrome.
Encantados de compartir un interesante debate, coordinado con Zogenix, sobre la [...]
-
It has been a pleasure to coordinate, together with Zogenix, a project directed to provide information, training and contribute to empowerment of patients suffering from Dravet Syndrome and their caregiversIt has been a pleasure to coordinate, together with Zogenix, a project directed to provide information, training and contribute to empowerment of patients suffering from Dravet Syndrome and their caregivers
It has been a pleasure to coordinate, together with Zogenix, a project directed to provide information, training and contribute to empowerment of patients suffering from Dravet Syndrome and their caregivers
Ha sido un placer coordinar, junto con Zogenix, un proyecto dirigido a contribui [...]
300 experts across country and regions claim to create a new HispaNice to assess innovative drugs in the Spanish NHS
Check the full information on the following link: https://elglobal.es/opinion/es [...]
-
Its now available the 4th edition of EDS Journal cotaining several articles about latest actuality. To highlight, there is an interesting entry about how to assess clinical benefit in order to accelerate access of innovative drugs where multidisciplinar experts have participatedIts now available the 4th edition of EDS Journal cotaining several articles about latest actuality. To highlight, there is an interesting entry about how to assess clinical benefit in order to accelerate access of innovative drugs where multidisciplinar experts have participated
Its now available the 4th edition of EDS Journal cotaining several articles about latest actuality. To highlight, there is an interesting entry about how to assess clinical benefit in order to accelerate access of innovative drugs where multidisciplinar experts have participated
Register and check the whole edition on the following link: https://economiadela [...]
The recordings of the 2nd Oncology Quality Care Symposium developed by ECO Foundation on behalf of ASCO are now available on its website
The recordings of the 2nd Oncology Quality Care Symposium developed by ECO Found [...]
-
Today at 1.30pm, Dr. Badía participates as an expert in the session “Cost, value and clinical benefit in the Oncology setting” to talk about MCDA for evaluating and positioning cancer treatments.Today at 1.30pm, Dr. Badía participates as an expert in the session “Cost, value and clinical benefit in the Oncology setting” to talk about MCDA for evaluating and positioning cancer treatments.
Today at 1.30pm, Dr. Badía participates as an expert in the session “Cost, value and clinical benefit in the Oncology setting” to talk about MCDA for evaluating and positioning cancer treatments.
Check more information about the symposium and join on streaming on the followin [...]
-
Dr. Badia, CEO Omakase Consulting, will participate in a conference meeting at the 2nd Oncology Quality Care Symposium (November, 12-13th) to present “MCDA for evaluating and positioning cancer treatments”Dr. Badia, CEO Omakase Consulting, will participate in a conference meeting at the 2nd Oncology Quality Care Symposium (November, 12-13th) to present “MCDA for evaluating and positioning cancer treatments”
Dr. Badia, CEO Omakase Consulting, will participate in a conference meeting at the 2nd Oncology Quality Care Symposium (November, 12-13th) to present “MCDA for evaluating and positioning cancer treatments”
On November 12-13th takes place the second Oncology Quality Care Symposium. The [...]